Treatment	B:C0087111
Patterns	I:C0087111
and	O
Outcomes	O
in	O
Patients	O
with	O
Varicose	O
Veins	I:C0042345
Approximately	O
24	O
%	O
of	O
adults	O
in	O
the	O
United	O
States	I:C0041703
have	O
visible	O
varicose	O
veins	I:C0042345
,	O
and	O
an	O
estimated	O
6	O
%	O
have	O
evidence	O
of	O
advanced	O
chronic	O
venous	O
disease	I:C0235522
.	O

Treatment	O
Patterns	I:C0087111
and	O
Outcomes	O
in	O
Patients	O
with	O
Varicose	B:C0042345
Veins	I:C0042345
Approximately	O
24	O
%	O
of	O
adults	O
in	O
the	O
United	O
States	I:C0041703
have	O
visible	O
varicose	O
veins	I:C0042345
,	O
and	O
an	O
estimated	O
6	O
%	O
have	O
evidence	O
of	O
advanced	O
chronic	O
venous	O
disease	I:C0235522
.	O

Treatment	O
Patterns	I:C0087111
and	O
Outcomes	O
in	O
Patients	O
with	O
Varicose	O
Veins	I:C0042345
Approximately	O
24	O
%	O
of	O
adults	O
in	O
the	O
United	B:C0041703
States	I:C0041703
have	O
visible	O
varicose	O
veins	I:C0042345
,	O
and	O
an	O
estimated	O
6	O
%	O
have	O
evidence	O
of	O
advanced	O
chronic	O
venous	O
disease	I:C0235522
.	O

Treatment	O
Patterns	I:C0087111
and	O
Outcomes	O
in	O
Patients	O
with	O
Varicose	O
Veins	I:C0042345
Approximately	O
24	O
%	O
of	O
adults	O
in	O
the	O
United	O
States	I:C0041703
have	O
visible	O
varicose	B:C0042345
veins	I:C0042345
,	O
and	O
an	O
estimated	O
6	O
%	O
have	O
evidence	O
of	O
advanced	O
chronic	O
venous	O
disease	I:C0235522
.	O

Treatment	O
Patterns	I:C0087111
and	O
Outcomes	O
in	O
Patients	O
with	O
Varicose	O
Veins	I:C0042345
Approximately	O
24	O
%	O
of	O
adults	O
in	O
the	O
United	O
States	I:C0041703
have	O
visible	O
varicose	O
veins	I:C0042345
,	O
and	O
an	O
estimated	O
6	O
%	O
have	O
evidence	O
of	O
advanced	O
chronic	O
venous	B:C0235522
disease	I:C0235522
.	O

The	O
majority	O
of	O
individuals	B:C0237401
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	B:C0042345
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	B:C0087111
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	B:C1457887
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	B:C0234238
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	B:C0030252
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	B:C0015672
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	B:C0033774
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	B:C0235439
swelling	I:C0235439
,	O
and	O
tenderness	O
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

The	O
majority	O
of	O
individuals	O
with	O
varicose	O
veins	I:C0042345
seek	O
treatment	O
because	O
of	O
symptoms	O
,	O
such	O
as	O
aching	O
,	O
throbbing	O
,	O
fatigue	O
,	O
pruritus	O
,	O
ankle	O
swelling	I:C0235439
,	O
and	O
tenderness	B:C0234233
,	O
rather	O
than	O
cosmetic	O
reasons	O
.	O

Furthermore	O
,	O
varicose	B:C0042345
veins	I:C0042345
are	O
a	O
manifestation	O
of	O
chronic	O
venous	I:C1306557
insufficiency	I:C1306557
,	O
which	O
can	O
progress	O
to	O
leg	O
pain	I:C0023222
,	O
leg	O
edema	I:C0235886
,	O
chronic	O
skin	I:C1399787
changes	I:C1399787
,	O
and	O
nonhealing	O
ulcers	O
.	O

Furthermore	O
,	O
varicose	O
veins	I:C0042345
are	O
a	O
manifestation	O
of	O
chronic	B:C1306557
venous	I:C1306557
insufficiency	I:C1306557
,	O
which	O
can	O
progress	O
to	O
leg	O
pain	I:C0023222
,	O
leg	O
edema	I:C0235886
,	O
chronic	O
skin	I:C1399787
changes	I:C1399787
,	O
and	O
nonhealing	O
ulcers	O
.	O

Furthermore	O
,	O
varicose	O
veins	I:C0042345
are	O
a	O
manifestation	O
of	O
chronic	O
venous	I:C1306557
insufficiency	I:C1306557
,	O
which	O
can	O
progress	O
to	O
leg	B:C0023222
pain	I:C0023222
,	O
leg	O
edema	I:C0235886
,	O
chronic	O
skin	I:C1399787
changes	I:C1399787
,	O
and	O
nonhealing	O
ulcers	O
.	O

Furthermore	O
,	O
varicose	O
veins	I:C0042345
are	O
a	O
manifestation	O
of	O
chronic	O
venous	I:C1306557
insufficiency	I:C1306557
,	O
which	O
can	O
progress	O
to	O
leg	O
pain	I:C0023222
,	O
leg	B:C0235886
edema	I:C0235886
,	O
chronic	O
skin	I:C1399787
changes	I:C1399787
,	O
and	O
nonhealing	O
ulcers	O
.	O

Furthermore	O
,	O
varicose	O
veins	I:C0042345
are	O
a	O
manifestation	O
of	O
chronic	O
venous	I:C1306557
insufficiency	I:C1306557
,	O
which	O
can	O
progress	O
to	O
leg	O
pain	I:C0023222
,	O
leg	O
edema	I:C0235886
,	O
chronic	B:C1399787
skin	I:C1399787
changes	I:C1399787
,	O
and	O
nonhealing	O
ulcers	O
.	O

Furthermore	O
,	O
varicose	O
veins	I:C0042345
are	O
a	O
manifestation	O
of	O
chronic	O
venous	I:C1306557
insufficiency	I:C1306557
,	O
which	O
can	O
progress	O
to	O
leg	O
pain	I:C0023222
,	O
leg	O
edema	I:C0235886
,	O
chronic	O
skin	I:C1399787
changes	I:C1399787
,	O
and	O
nonhealing	O
ulcers	B:C0041582
.	O

To	O
assess	O
varicose	B:C0042345
vein	I:C0042345
treatment	O
patterns	I:C0087111
and	O
their	O
corresponding	O
outcomes	O
,	O
including	O
additional	O
treatment	O
rates	O
,	O
disease	O
progression	I:C0242656
to	O
new	O
ulcers	O
,	O
and	O
associated	O
costs	O
from	O
a	O
US	O
perspective	O
.	O

To	O
assess	O
varicose	O
vein	I:C0042345
treatment	B:C0087111
patterns	I:C0087111
and	O
their	O
corresponding	O
outcomes	O
,	O
including	O
additional	O
treatment	O
rates	O
,	O
disease	O
progression	I:C0242656
to	O
new	O
ulcers	O
,	O
and	O
associated	O
costs	O
from	O
a	O
US	O
perspective	O
.	O

To	O
assess	O
varicose	O
vein	I:C0042345
treatment	O
patterns	I:C0087111
and	O
their	O
corresponding	O
outcomes	O
,	O
including	O
additional	O
treatment	O
rates	O
,	O
disease	B:C0242656
progression	I:C0242656
to	O
new	O
ulcers	O
,	O
and	O
associated	O
costs	O
from	O
a	O
US	O
perspective	O
.	O

To	O
assess	O
varicose	O
vein	I:C0042345
treatment	O
patterns	I:C0087111
and	O
their	O
corresponding	O
outcomes	O
,	O
including	O
additional	O
treatment	O
rates	O
,	O
disease	O
progression	I:C0242656
to	O
new	O
ulcers	B:C0041582
,	O
and	O
associated	O
costs	O
from	O
a	O
US	O
perspective	O
.	O

To	O
assess	O
varicose	O
vein	I:C0042345
treatment	O
patterns	I:C0087111
and	O
their	O
corresponding	O
outcomes	O
,	O
including	O
additional	O
treatment	O
rates	O
,	O
disease	O
progression	I:C0242656
to	O
new	O
ulcers	O
,	O
and	O
associated	O
costs	O
from	O
a	O
US	B:C0041703
perspective	O
.	O

We	O
conducted	O
a	O
retrospective	O
claims	O
database	B:C0242356
study	O
using	O
data	O
from	O
the	O
Truven	O
Health	I:C0242356
MarketScan	I:C0242356
database	I:C0242356
.	O

We	O
conducted	O
a	O
retrospective	O
claims	O
database	O
study	B:C2603343
using	O
data	O
from	O
the	O
Truven	O
Health	I:C0242356
MarketScan	I:C0242356
database	I:C0242356
.	O

We	O
conducted	O
a	O
retrospective	O
claims	O
database	O
study	O
using	O
data	O
from	O
the	O
Truven	B:C0242356
Health	I:C0242356
MarketScan	I:C0242356
database	I:C0242356
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	B:C0011900
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	B:C0042345
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	B:C0599755
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	B:C0087111
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	B:C0038842
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	B:C0565514
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	B:C0543467
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	B:C0348007
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	B:C0850292
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	B:C0036435
,	O
or	O
multiple	O
therapies	O
.	O

Adults	O
who	O
were	O
newly	O
diagnosed	O
with	O
varicose	O
veins	I:C0042345
between	O
January	O
1	O
,	O
2008	O
,	O
and	O
June	O
30	O
,	O
2010	O
,	O
and	O
met	O
the	O
study	O
inclusion	O
criteria	O
were	O
eligible	O
to	O
participate	O
and	O
were	O
divided	O
into	O
6	O
cohorts	O
based	O
on	O
the	O
type	O
of	O
first	O
or	O
initial	O
therapy	O
they	O
received	O
after	O
the	O
index	O
diagnosis	O
date	O
,	O
including	O
surveillance	O
and	O
compression	O
therapy	I:C0565514
,	O
surgery	O
,	O
laser	O
ablation	I:C0348007
,	O
radiofrequency	O
ablation	I:C0850292
,	O
sclerotherapy	O
,	O
or	O
multiple	O
therapies	B:C0087111
.	O

The	O
patients	O
were	O
followed	O
for	O
2	O
years	O
after	O
the	O
index	O
diagnosis	O
date	O
to	O
assess	O
their	O
treatment	B:C0087111
patterns	I:C0087111
and	O
outcomes	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	B:C0038842
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	B:C0242656
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	B:C0565514
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	B:C0348007
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	B:C0850292
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	B:C0036435
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	B:C0543467
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	O
.	O

Of	O
these	O
patients	O
,	O
100,072	O
(	O
69.5	O
%	O
)	O
were	O
under	O
surveillance	O
for	O
disease	O
progression	I:C0242656
and	O
/	O
or	O
received	O
compression	O
therapy	I:C0565514
;	O
14,007	O
(	O
9.7	O
%	O
)	O
received	O
laser	O
ablation	I:C0348007
;	O
9125	O
(	O
6.3	O
%	O
)	O
received	O
radiofrequency	O
ablation	I:C0850292
;	O
4778	O
(	O
3.3	O
%	O
)	O
received	O
sclerotherapy	O
;	O
4851	O
(	O
3.4	O
%	O
)	O
had	O
surgery	O
;	O
and	O
11,265	O
(	O
7.8	O
%	O
)	O
received	O
multiple	O
therapies	B:C0087111
.	O

During	O
the	O
2	O
-	O
year	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
period	O
,	O
among	O
patients	O
receiving	O
interventional	O
treatment	I:C0184661
,	O
54.7	O
%	O
of	O
patients	O
received	O
additional	O
interventional	O
treatment	I:C0184661
(	O
either	O
with	O
the	O
same	O
mode	O
or	O
a	O
different	O
mode	O
from	O
the	O
initial	O
treatment	O
)	O
;	O
30.1	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
(	O
not	O
including	O
additional	O
procedures	O
)	O
at	O
8	O
weeks	O
;	O
and	O
44.2	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
at	O
1	O
year	O
after	O
the	O
initial	O
interventional	O
therapy	I:C0184661
.	O

During	O
the	O
2	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
,	O
among	O
patients	O
receiving	O
interventional	B:C0184661
treatment	I:C0184661
,	O
54.7	O
%	O
of	O
patients	O
received	O
additional	O
interventional	O
treatment	I:C0184661
(	O
either	O
with	O
the	O
same	O
mode	O
or	O
a	O
different	O
mode	O
from	O
the	O
initial	O
treatment	O
)	O
;	O
30.1	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
(	O
not	O
including	O
additional	O
procedures	O
)	O
at	O
8	O
weeks	O
;	O
and	O
44.2	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
at	O
1	O
year	O
after	O
the	O
initial	O
interventional	O
therapy	I:C0184661
.	O

During	O
the	O
2	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
,	O
among	O
patients	O
receiving	O
interventional	O
treatment	I:C0184661
,	O
54.7	O
%	O
of	O
patients	O
received	O
additional	O
interventional	B:C0184661
treatment	I:C0184661
(	O
either	O
with	O
the	O
same	O
mode	O
or	O
a	O
different	O
mode	O
from	O
the	O
initial	O
treatment	O
)	O
;	O
30.1	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
(	O
not	O
including	O
additional	O
procedures	O
)	O
at	O
8	O
weeks	O
;	O
and	O
44.2	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
at	O
1	O
year	O
after	O
the	O
initial	O
interventional	O
therapy	I:C0184661
.	O

During	O
the	O
2	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
,	O
among	O
patients	O
receiving	O
interventional	O
treatment	I:C0184661
,	O
54.7	O
%	O
of	O
patients	O
received	O
additional	O
interventional	O
treatment	I:C0184661
(	O
either	O
with	O
the	O
same	O
mode	O
or	O
a	O
different	O
mode	O
from	O
the	O
initial	O
treatment	O
)	O
;	O
30.1	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	B:C0042345
veins	I:C0042345
(	O
not	O
including	O
additional	O
procedures	O
)	O
at	O
8	O
weeks	O
;	O
and	O
44.2	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
at	O
1	O
year	O
after	O
the	O
initial	O
interventional	O
therapy	I:C0184661
.	O

During	O
the	O
2	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
,	O
among	O
patients	O
receiving	O
interventional	O
treatment	I:C0184661
,	O
54.7	O
%	O
of	O
patients	O
received	O
additional	O
interventional	O
treatment	I:C0184661
(	O
either	O
with	O
the	O
same	O
mode	O
or	O
a	O
different	O
mode	O
from	O
the	O
initial	O
treatment	O
)	O
;	O
30.1	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
(	O
not	O
including	O
additional	O
procedures	O
)	O
at	O
8	O
weeks	O
;	O
and	O
44.2	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	B:C0042345
veins	I:C0042345
at	O
1	O
year	O
after	O
the	O
initial	O
interventional	O
therapy	I:C0184661
.	O

During	O
the	O
2	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
,	O
among	O
patients	O
receiving	O
interventional	O
treatment	I:C0184661
,	O
54.7	O
%	O
of	O
patients	O
received	O
additional	O
interventional	O
treatment	I:C0184661
(	O
either	O
with	O
the	O
same	O
mode	O
or	O
a	O
different	O
mode	O
from	O
the	O
initial	O
treatment	O
)	O
;	O
30.1	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
(	O
not	O
including	O
additional	O
procedures	O
)	O
at	O
8	O
weeks	O
;	O
and	O
44.2	O
%	O
had	O
>	O
1	O
postintervention	O
claim	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
at	O
1	O
year	O
after	O
the	O
initial	O
interventional	B:C0184661
therapy	I:C0184661
.	O

A	O
majority	O
of	O
the	O
patients	O
in	O
the	O
study	B:C2603343
received	O
conservative	O
management	O
.	O

For	O
patients	O
receiving	O
interventional	B:C0184661
therapy	I:C0184661
,	O
the	O
outcomes	O
varied	O
based	O
on	O
the	O
treatment	O
cohort	O
.	O

For	O
patients	O
receiving	O
interventional	O
therapy	I:C0184661
,	O
the	O
outcomes	O
varied	O
based	O
on	O
the	O
treatment	B:C0087111
cohort	O
.	O

For	O
patients	O
receiving	O
interventional	O
therapy	I:C0184661
,	O
the	O
outcomes	O
varied	O
based	O
on	O
the	O
treatment	O
cohort	B:C0599755
.	O

The	O
surgery	B:C0543467
cohort	O
was	O
associated	O
with	O
the	O
most	O
favorable	O
outcome	O
regarding	O
the	O
need	O
for	O
additional	O
treatment	O
and	O
evidence	O
of	O
postintervention	O
claims	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
,	O
followed	O
by	O
the	O
multiple	O
therapies	O
cohort	O
.	O

The	O
surgery	O
cohort	B:C0599755
was	O
associated	O
with	O
the	O
most	O
favorable	O
outcome	O
regarding	O
the	O
need	O
for	O
additional	O
treatment	O
and	O
evidence	O
of	O
postintervention	O
claims	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
,	O
followed	O
by	O
the	O
multiple	O
therapies	O
cohort	O
.	O

The	O
surgery	O
cohort	O
was	O
associated	O
with	O
the	O
most	O
favorable	O
outcome	O
regarding	O
the	O
need	O
for	O
additional	O
treatment	B:C0087111
and	O
evidence	O
of	O
postintervention	O
claims	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
,	O
followed	O
by	O
the	O
multiple	O
therapies	O
cohort	O
.	O

The	O
surgery	O
cohort	O
was	O
associated	O
with	O
the	O
most	O
favorable	O
outcome	O
regarding	O
the	O
need	O
for	O
additional	O
treatment	O
and	O
evidence	O
of	O
postintervention	O
claims	O
for	O
symptomatic	O
varicose	B:C0042345
veins	I:C0042345
,	O
followed	O
by	O
the	O
multiple	O
therapies	O
cohort	O
.	O

The	O
surgery	O
cohort	O
was	O
associated	O
with	O
the	O
most	O
favorable	O
outcome	O
regarding	O
the	O
need	O
for	O
additional	O
treatment	O
and	O
evidence	O
of	O
postintervention	O
claims	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
,	O
followed	O
by	O
the	O
multiple	O
therapies	B:C0087111
cohort	O
.	O

The	O
surgery	O
cohort	O
was	O
associated	O
with	O
the	O
most	O
favorable	O
outcome	O
regarding	O
the	O
need	O
for	O
additional	O
treatment	O
and	O
evidence	O
of	O
postintervention	O
claims	O
for	O
symptomatic	O
varicose	O
veins	I:C0042345
,	O
followed	O
by	O
the	O
multiple	O
therapies	O
cohort	B:C0599755
.	O

A	O
better	O
understanding	O
of	O
these	O
treatment	O
outcomes	O
in	O
the	O
real	O
-	O
world	O
setting	O
may	O
affect	O
new	O
strategies	O
to	O
improve	O
the	O
management	B:C0030677
of	O
patients	O
with	O
varicose	O
veins	I:C0042345
.	O

A	O
better	O
understanding	O
of	O
these	O
treatment	O
outcomes	O
in	O
the	O
real	O
-	O
world	O
setting	O
may	O
affect	O
new	O
strategies	O
to	O
improve	O
the	O
management	O
of	O
patients	O
with	O
varicose	B:C0042345
veins	I:C0042345
.	O

